Abstract: CRISPR-Cas12a (Cpf1) proteins are RNA-guided DNA targeting enzymes that bind and cut DNA as components of bacterial adaptive immune systems. Like CRISPR-Cas9, Cas12a
with guide RNA sequences targeting a circular, single-stranded M13 DNA phage. In contrast to SpCas9, we were surprised to find that LbCas12a induced rapid and complete degradation of M13 by a cleavage mechanism that could not be explained by sequence-specific DNA cutting (Fig. 1b) . This ssDNA shredding activity, not observed using an LbCas12a protein containing inactivating mutations in the RuvC catalytic domain, raised the possibility that a target-bound LbCas12a could degrade any ssDNA, regardless of complementarity to the guide RNA. To test this idea, we assembled LbCas12a or SpCas9 with a different guide RNA and complementary ssDNA with no sequence homology to M13 phage genome sequence, and added M13 DNA to 4 the reaction. Remarkably, LbCas12a catalyzed M13 degradation only in the presence of this complementary ssDNA "activator", an activity not observed for SpCas9 (Fig. 1c) . These findings reveal that binding of LbCas12a to a guide-complementary ssDNA unleashes robust, non-specific ssDNA trans-cleavage activity.
We next investigated the requirements for LbCas12-catalyzed trans-cleavage activity.
Using a fluorophore quencher (FQ)-labeled reporter assay (19, 20) , we assembled LbCas12a To determine how LbCas12a-catalyzed ssDNA cleavage activity relates to site-specific dsDNA cutting, we tested the length requirements of the target strand (TS) and non-target strand (NTS) for LbCas12a activation using radiolabeled oligonucleotides. Although TS cutting occurred irrespective of the NTS length (figs. S3A-B), NTS cleavage occurred only when the TS contained at least 15 nucleotides (nt) of complementarity with the crRNA (fig. S3C ). This showed that TS recognition is a prerequisite for NTS cutting. To test whether LbCas12a remains active for non-specific ssDNA cleavage after sequence-specific binding and cleavage of a dsDNA substrate, we first cut a dsDNA plasmid with an LbCas12a-crRNA complex, and introduced an unrelated dsDNA or ssDNA to the reaction (Fig. 2a) . Whereas non-specific dsDNA substrate remained intact, the ssDNA was rapidly degraded in a RuvC-domain dependent manner (Fig. 2a; figs. S4, S5) . Together, these results show that RNA-guided DNA 5 binding activates LbCas12a for both site-specific dsDNA cutting and non-specific ssDNA transcleavage.
The rapid degradation of a trans substrate suggested that the kinetics of LbCas12a-catalyzed site-specific dsDNA (cis-) cleavage and non-specific ssDNA (trans-) cleavage are fundamentally different. Stoichiometric titration experiments showed that cis-cleavage is singleturnover (21) (Fig. 2b) , whereas trans-cleavage is multiple-turnover (Fig. 2c) Fig. 2d; fig. S6 ). These differences suggest that the NTS of the dsDNA activator helps stabilize the Cas12a complex in an optimal conformation for transssDNA cutting.
We next tested the specificity of trans-cleavage activation using either a ssDNA or dsDNA activator. We found that the PAM sequence required for dsDNA binding by CRISPRCas12a (21) is critical for catalytic activation by a crRNA-complementary dsDNA (8, 23) , but not for a crRNA-complementary ssDNA (Fig. 3a) . Two base-pair (bp) mismatches introduced along the crRNA-complementary sequence of either a ssDNA or dsDNA activator molecule slowed the trans-cleavage rate of a ssDNA-FQ reporter by up to ~100 fold, depending on the mismatch position. For only the dsDNA activator, alterations to the PAM sequence or mismatches between the crRNA and PAM-adjacent "seed region" also had large inhibitory effects on trans-ssDNA cleavage activity ( Fig. 3b; fig. S7 For radiolabeled cleavage assays, PAGE-purified DNA oligos were prepared as described.
sgRNA templates were PCR amplified from a pUC19 vector or overlapping primers containing a T7 promoter, 20 nucleotide target sequence and an sgRNA scaffold. The amplified PCR product served as the DNA template for in vitro transcription reactions, which were 17 performed as described (1). crRNAs were transcribed in vitro using a single-stranded DNA template containing a T7 promoter, repeat and spacer in the reverse complement orientation, which was annealed to T7 forward primer in 1× hybridization buffer. All DNA and RNA substrates are listed in Table S1 . For radiolabeled cleavage assays, the substrates used were 5′-end-labeled with T4 PNK (NEB) in the presence of gamma 32 P-ATP. For dsDNA substrates, the non-target strand was first 5′-end-labeled and then annealed with excess corresponding target strand. The concentrations of Cas12a (or SpCas9), guide RNA and 32 P-labeled substrates used in the reaction were 30 nM, 36 nM and 1-3 nM, respectively. Reactions were incubated for 30 min (unless otherwise stated) at 37°C (or 47.5°C for the thermophilic AacCas12b) and quenched with formamide loading buffer (final concentration 45% formamide and 15 mM EDTA, with trace amount of xylene cyanol and bromophenol blue) for 3 min at 90°C. The substrates and products were resolved by 12% ureadenaturing PAGE gel and quantified with Amersham Typhoon (GE Healthcare). 18 For substrate turnover studies, the pre-assembled Cas12a-crRNA or Cas12a-crRNAactivator (target ssDNA or dsDNA) were incubated at 37°C for 10 min, and 30 nM of the preassembled RNP were used for each reaction with various substrate concentrations at 15, 30, 45, and 60 nM, respectively. 
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